ZYN 001

Drug Profile

ZYN 001

Alternative Names: D-glyceric acid ester delta 9-tetrahydrocannabinol; Tetrahydrocannabinol prodrug; Tetrahydrocannabinol prodrug transdermal patch; THC prodrug; THC prodrug transdermal patch; ZYN001

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zynerba Pharmaceuticals
  • Class Antiemetics; Cannabinoids; Esters; Neuroprotectants; Non-opioid analgesics; Sugar acids
  • Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer pain
  • Discontinued Fibromyalgia; Neuropathic pain

Most Recent Events

  • 03 Jan 2018 Discontinued - Phase-I for Fibromyalgia (In volunteers) in USA (Transdermal)
  • 03 Jan 2018 Discontinued - Phase-I for Neuropathic pain (In volunteers) in USA (Transdermal)
  • 14 Nov 2017 Zynerba Pharmaceuticals plans a phase II trial for Gilles de la Tourette's syndrome in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top